NeoTool expands testing features, code set functionality of integration engine

NeoTool has released its latest version of NeoIntegrate, which continues to optimize the configure-test-manage-protect cycle for healthcare interfacing.

The company said NeoIntegrate’s newest features and functionality includes:
  • Greater interface quality through new test message manager functionality;
  • Re-usability of data transformation logic through added action list calls;
  • Expanded interface requirements with new code set translation capabilities; and
  • Ongoing interface management and insights with graphical view of message flow statistics.
The Plano, Texas-based NeoTool said the latest NeoIntegrate release offers testing features, such as new loading options that allow users to load test files as a single, unparsed message, as a file of messages, or as an individual message. In addition, the new test message manager offers testing of messages without the requirement to create customized files. Users can select messages in a file or folder for testing and store remaining messages for future use.

With the addition of action list call functionality, the company said its interface analysts configure re-usable subsets of data logic and mapping. Benefits of using the new functionality include: re-use of frequently used groups of actions; test a sub-set of actions, independent of the rest of the action list; insulate a group of actions for separate development and testing; and maintain frequently used actions.

NeoTool said NeoIntegrate’s code translation features provides the capability to productively address the varying code sets that are sent and received from diverse providers within a healthcare community. Mappings are now implemented and maintained within NeoIntegrate’s configuration settings with no more manual look-up.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.